A new agreement between Sorrento Therapeutics Inc. and CHA Biotech Co. Ltd. underscores the ongoing efforts by South Korean biopharma firms to grab leading positions in the still early stage but rapidly growing immuno-oncology sector by seeking collaborations with international partners.
San Diego-based clinical stage company Sorrento and CHA, which has its R&D focus in stem cells and cell therapeutics, will...







